Cart
sales@molnova.com
NSC23005 sodium
CAS No. 1796596-46-7
NSC23005 sodium( NSC 23005 sodium | NSC-23005 sodium | p18-IN-40 )
Catalog No. M12713 CAS No. 1796596-46-7
A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 105 | In Stock |
|
| 25MG | 231 | In Stock |
|
| 50MG | 413 | In Stock |
|
| 100MG | 592 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSC23005 sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
-
DescriptionA novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM; inhibits p18, and then activates CDK4/6, promotes HSCs expansion in both murine and human models; shows no activity in promoting the proliferation of leukemia cells, and no significant cytotoxicity toward 32D cells or HSCs.
-
In VitroNSC23005 sodium (Compound 40) is a novel class of INK4C (p18INK4C or p18) small molecule inhibitor (p18SMIs), which is initially found by in silico 3D screening. NSC23005 sodium shows the most potent bioactivity in hematopoietic stem cells (HSCs) expansion (ED50=5.21 nM). Notably, NSC23005 sodium does not show significant cytotoxicity toward 32D cells or HSCs, nor does it augment leukemia cell proliferation. NSC23005 sodium (ED50=5.21 nM), shows no activity in promoting the proliferation of leukemia cells.
-
In VivoNSC23005 sodium selectively promote HSCs division by inhibiting p18, thereby activating CDK4/6. NSC23005 sodium is a novel and effective p18 inhibitor in promoting HSCs expansion in both murine and human models.
-
SynonymsNSC 23005 sodium | NSC-23005 sodium | p18-IN-40
-
PathwayAngiogenesis
-
TargetCDK
-
Recptorp18INK4C
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1796596-46-7
-
Formula Weight305.33
-
Molecular FormulaC13H16NNaO4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need ultrasonic)
-
SMILESC1CCC(CC1)NS(=O)(=O)C2=CC=C(C=C2)C(=O)[O-].[Na+]
-
Chemical NameBenzoic acid, 4-[(cyclohexylamino)sulfonyl]-, sodium salt (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xie XQ, et al. Sci Rep. 2015 Dec 18;5:18115.
molnova catalog
related products
-
BRD6989
A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex; displays no activity against several CDKs involved in cell cycle including CDK19 (IC50>30 uM).
-
Bohemine
Bohemine is a cyclin-dependent kinase inhibitor.
-
Trilaciclib hydrochl...
Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.
